Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2025-11-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
第五届监事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yunnan Watson Biotechnology Co., Ltd. It details decisions made in a specific Supervisory Board meeting, including the abolition of the Supervisory Board, appointment of the 2025 audit firm, and approval of credit lines for subsidiaries. It is not a full audit report or annual report but a formal announcement of board meeting resolutions. The document is relatively short (1577 characters) and serves as an official disclosure of board decisions rather than detailed financial data or report content. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company governance and management decisions.
2025-11-28 Chinese
关于子公司收到13价肺炎结合疫苗埃及上市许可证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary receiving a marketing authorization license for a vaccine in Egypt. It contains no financial statements, no detailed financial data, no regulatory certifications, or meeting materials. It is an update on a business development related to product approval and market expansion. The document is short (976 characters) and is an announcement of a specific event rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance matters. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-11-26 Chinese
关于水痘减毒活疫苗临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the acceptance of their clinical trial application for a varicella live attenuated vaccine by the National Medical Products Administration. It contains no financial data, no financial statements, no management discussion of financial results, and no regulatory certifications. The document is an official announcement about a regulatory acceptance related to clinical trial application, not a financial report or management report. It is also not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-11-21 Chinese
关于注销部分募集资金专用账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain special accounts for raised funds (募集资金专用账户) by Yunnan Watson Biotechnology Co., Ltd. It details the background of the fundraising, the management of the raised funds, the completion of a project funded by these raised funds, and the cancellation of specific bank accounts related to these funds. The document is a formal public announcement about the status and management of fundraising accounts, not a financial report, audit, or detailed financial statement. It does not contain financial statements or substantive financial data but rather updates on capital management and account status. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3090 characters, which is relatively short and consistent with an announcement rather than a full report. No indication of voting results, board changes, or legal proceedings is present. Hence, the classification is CAP with high confidence.
2025-11-20 Chinese
关于获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a listed company about receiving government subsidies, detailing the amount, classification, and expected impact on financial results. It includes no financial statements or detailed financial analysis but rather a disclosure of a specific event affecting the company's finances. The document length is short (1162 characters) and it is an announcement of a financial event rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about government grants received, which is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-10-30 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司 2025 年第三季度报告', which translates to 'Yunnan Watson Biotechnology Co., Ltd. 2025 Third Quarter Report'. It contains detailed financial data including income, profit, cash flow, balance sheet, and explanations of financial changes for the third quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period ending September 30, 2025. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-10-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.